Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6666 羅麗芬-KY. Please read: https://finlab.finance/en/setup?stock=6666

No install, open FinLab Studio

6666

羅麗芬-KY Biotech & Healthcare As of 2026-06-17 Updated daily after market close

steady quality, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 羅麗芬-KY to your watchlist to track signal changes on your next visit.
Valuation 70Quality 37Growth 77Momentum 48Chips 12

Is 羅麗芬-KY a buy? Fundamentals and valuation first

  • Above-average profitability.Operating margin is in the 41th market percentile. Latest quarterly ROE ≈ 0.6%.

  • Valuation is neutral.PE is in the 45th market percentile; within its own history, PE is around the 27th percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -4.4% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 35.1%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.31
BearishNeutralBullish

Institutional rotation, concentration steady — bullish

  • Institutional rotation, concentration steady — bullish
  • 合庫證券 holds 103 lots
  • sellers have 30 lots left, ~55 sessions to clear

Window from 2026-01-17 · Price -4% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 合庫證券 has accumulated 103 lots since the start (sold 0%), still adding.
  • Main distributor 富邦-花蓮 peaked at 26 lots, has sold 27%, 19 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.00pp, mid holders +0, retail -0.00pp — little change.
  • Foreign hedge-desk net short Net short -34 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
合庫證券富邦-嘉義群益金鼎-彰化元大-敦南凱基-湖口元大-北投
Distributing
富邦-花蓮統一-三重凱基-站前台新-虎尾摩根大通元大-六合
Desks
own scale
台灣企銀-北高雄富邦-台北台灣摩根士丹利凱基-台北
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 合庫證券 +103
    sold 0%· still adding
  • 富邦-嘉義 +61
    sold 0%· still adding
  • 群益金鼎-彰化 +54
    sold 0%· still adding
  • 元大-敦南 +51
    sold 0%· still adding
  • 凱基-湖口 +35
    sold 0%
  • 元大-北投 +32
    sold 0%· still adding

Distributing

  • 富邦-花蓮 19 left
    sold 27%· paused recently
  • 統一-三重 10 left
    sold 60%· ~7 sessions to clear
  • 凱基-站前 11 left
    sold 27%· ~55 sessions to clear
  • 台新-虎尾 4 left
    sold 64%· paused recently
  • 摩根大通 3 left
    sold 67%· ~15 sessions to clear
  • 元大-六合 1 left
    sold 88%· paused recently

Desks

  • 台灣企銀-北高雄 -60
    unclassified
  • 富邦-台北 -34
    unclassified
  • 台灣摩根士丹利 -31
    hedge desk · will cover
  • 凱基-台北 -30
    day-trade · selling pressure
Still selling 30 lots ~55 sessions to bottom at most
Recent buy/sell force +246 absorbed / -31 sold buyers slightly ahead
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 35.11%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

27 historical occurrences (since 2018-11-19)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 52%, Sample 25, Median +0.49%, Excess +0.36%, Beat mkt rate 36%；60-day: Win 40%, Sample 25, Median -2.98%, Excess -7.99%, Beat mkt rate 24%；120-day: Win 40%, Sample 25, Median -9.43%, Excess -12.45%, Beat mkt rate 24%

120 days after: historical avg -2.81%

20-day +3%
60-day -1.72%
120-day -2.81%
20-day
60-day
120-day
Win
52%
40%
40%
Sample
25
25
25
Median
+0.49%
-2.98%
-9.43%
Excess
+0.36%
-7.99%
-12.45%
Beat mkt rate
36%
24%
24%

Over 25 occurrences, 120-day forward avg declined 2.81%, lagged the market by 12.45 pts; win rate 40%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 0Insufficient data
20-40 You are here113-0.7% -0.1% 49.6% -68.4%
40-60 72-21.1% -20.8% 0% -42.1%
60-80 182-7.8% -15.8% 29.1% -13.9%
80-100 484+0.2% -14.5% 33.3% -24.6%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 19.81, at the 27.1th percentile of its own history (20-40 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
Now
-10.6%
Win rate 36.1% Excess -46.7%
83d
-10.8%
Win rate 15.9% Excess -24.4%
69d
+1.4%
Win rate 50.7% Excess -9.1%
219d
60-day momentum down
+6.1%
Win rate 52.8% Excess -21.1%
123d
-10.5%
Win rate 19.1% Excess -14.1%
131d
+3%
Win rate 45.3% Excess -2.8%
344d

Currently in “Cheap (own-history bottom 1/3) × 60-day momentum up”: across 83 historical days, 120-day forward avg declined 10.6%, win rate 36.1%, lagged the market by 46.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

23 times historically; 60-day forward avg -2.12%, win rate 31.8%, beating the market by -7.97 pts on average.

What does 羅麗芬-KY do? Company profile

生技醫療業；美容保養品、專業美容與雙美通路 台灣證券交易所上市

Overview

6666 對應證券為羅麗芬控股股份有限公司，簡稱羅麗芬-KY，為第一上市 KY 公司普通股，外國企業註冊地為開曼群島。公開資訊觀測站／交易所 OpenAPI 顯示，公司成立日為 2016-09-21，上市日為 2018-11-19，地址為新北市中和區圓通路301號生醫科技大樓15樓，董事長為嘉黛國際有限公司代表人羅麗芬，總經理為饒煥文，發言人為王志富，實收資本額新台幣473,880,000元，已發行普通股47,388,000股。公司經營源流可追溯至2002年於廈門成立之美容保養品事業，後以 KY 架構於台灣第一上市。主要股東／董監經理人持股資訊以公開可查資料彙整：嘉黛國際有限公司約15,216,300股、約32.11%；賦達（香港）有限公司約5,406,122股、約11.41%；賀士郡約127,600股、約0.27%。董監持股比例近期約43.7%。員工規模未在可快速查證來源中取得穩定數字，故不填具體人數。

Business

公司主要從事面部類美容保養品之研發、製造、銷售，以及經銷商管理、教育培訓、專業美容院通路、日化線 CS 通路、雙美直營／加盟連鎖與電商通路。核心品牌與產品包括葛林若、聖迪妮爾、黛昂絲等臉部保養品牌，近年亦推動明星商品如出水芙蓉霜，以及與產學研合作之煥能修護安膚水、逆時青春霜、梔萃多肽緊塑霜、多肽緊致抗皺精華液等。2025年度年報摘要顯示，營收結構為美容保養品新台幣1,017,446千元、佔91.42%，其他新台幣95,526千元、佔8.58%；2025年度合併營收新台幣1,112,972千元，較2024年度新台幣1,126,524千元小幅減少約1%；歸屬母公司淨利新台幣114,730千元，較2024年度新台幣80,734千元成長約42%。區域別方面，中國大陸2025年營收新台幣1,063,498千元、佔約96%，仍為最大市場。商業模式以自有品牌自製產品，透過區域經銷商、專業美容院、CS 日化門店、雙美門店與電商平台觸及終端消費者；專業美容院由美容顧問與課程服務帶動產品銷售，雙美通路結合生活美容與醫學美容概念，電商則以小紅書、抖音、淘寶天貓、直播與私域流量導入其他通路。2026年公開新聞指出，兩岸美容院約4,000多家、CS日化通路約2,000多家，合計約6,000多家門店；2025年新聞亦指出日化線已有20多家經銷商及逾1,200家銷售店家。

Outlook 2025–2028

2025年：公司面對中國總體經濟與房地產低迷、終端消費理性化、線上增速放緩等壓力，主軸為強化 O2O、三大／四大通路協同、日化線開拓與雙美直營店；2025年年報摘要指出以自研原料升級後之明星商品出水芙蓉霜帶動專業線營收佔比提升，並以自研替代外採改善毛利率。2026年：公司計畫在中國專業美容院通路與電商同步首發與訊聯生技、臺北醫學大學合作之新品，透過小紅書、抖音、KOL／KOC、明星直播、淘寶天貓與私域小程序形成全域導流；日化線 CS 通路完成庫存去化後，將借助電商推廣深入二、三線城市及下沉市場；雙美通路規劃在廈門新增6至8家線下服務店，並在台灣原址改裝設立忠孝雙美直營店。2027年：公司年報計畫文字表示，擇優3個一、二線城市開放社區型小型美容連鎖加盟，提供選址、培訓、供應鏈等整包方案。2028年：公司規劃全國加盟網路鋪開，取得加盟費與供貨毛利雙重收益。中長期成長動能包括中國化妝品市場回暖、國貨品牌份額提升、植物活性成分／植物微囊泡／植物碳點／外泌體等研發題材、自主原料商業化、雙美賽道與電商全域流量整合。主要風險包括中國消費降級與美容服務需求波動、化妝品監管與功效宣稱法規趨嚴、通路庫存與經銷商管理風險、電商流量成本上升、加盟展店回收期不如預期、人民幣匯率與 KY 公司治理資訊透明度風險。2027至2028展望多屬公司營運計畫與推估，尚非已實現事實。

Supply Chain

Upstream
  • 訊聯生物科技股份有限公司 1784 產學研／原料技術合作夥伴；公司年報摘要稱下半年與外泌體研發企業訊聯生技合作，使用外泌體粉末凍乾技術開發保養新品。
  • 臺北醫學大學 學研合作單位；公司年報摘要稱採用臺北醫學大學專利紅球薑天然抗老成分，屬大學研究機構，非台股掛牌公司。
  • 植物活性成分、植物微囊泡、植物碳點、自主開發原料供應與研發體系 公司自研與原料端能力；年報摘要提及深化植物活性成分研究、自主原料開發及應用，但未揭露具名供應商。
  • 包材、化妝品原料、製造設備與數位製造系統供應商 美容保養品製造所需上游；公開資料僅提到自製、自行建廠、AI智慧工廠及PLM／ERP／MES互聯方向，未查得具名供應商。
Downstream
  • 中國大陸區域經銷商 主要銷售中介；公司以經銷商模式銷售至美容院，經銷商多為未上市或未揭露名稱。
  • 專業美容院通路 核心終端通路；美容院透過美容顧問推薦保養課程與產品給終端消費者，2026年新聞稱兩岸美容院約4,000多家。
  • CS日化通路與產品銷售店家 日化線通路；2025年新聞稱已有20多家經銷商及超過1,200家銷售店家，2026年新聞稱 CS 日化通路約2,000多家。
  • 雙美直營與加盟連鎖門店 生活美容／醫學美容結合之服務通路；公司規劃廈門新增社區型小型美容門店、台灣新增忠孝雙美旗艦／直營店。
  • 抖音、小紅書、淘寶天貓與直播電商平台 電商與內容行銷下游平台；多為中國或境外平台／未於台股掛牌，用於種草、直播帶貨、會員與複購導流。
  • 終端消費者 最終需求來自美容保養、熟齡肌、敏感肌、醫美術後修護與高階療程消費族群。

Competitors

  • 麗豐-KY 4137 台股上市公司；美容產品、護理套組與中國美容連鎖加盟通路，常與羅麗芬-KY、佐登-KY並列美容通路三雄。
  • 佐登-KY 4190 台股上市公司；佐登妮絲美容保養品、SPA與輕醫美通路，與羅麗芬-KY在美容服務與產品銷售通路競爭。
  • 曜亞 4138 台股上櫃公司；醫美設備與醫美相關通路，屬美容／醫美概念競爭或替代標的。
  • 光麗-KY 6431 台股掛牌公司；化妝美容相關公司，公開競品列表將其列為同業。
  • 達爾膚 6523 台股上櫃公司；DR.WU 醫美保養品品牌，與羅麗芬-KY在保養品、醫美保養與通路市場競爭。
  • 霈方 6574 台股上櫃公司；美容保養品牌與百貨／電商通路，公開說明書與競品資料列為相近同業。
  • 軒郁 6703 台股上櫃公司；美妝保養品牌與電商營運能力強，屬美容保養品同業。
  • 雙美 4728 台股上櫃公司；膠原蛋白及醫美保養品相關，與雙美、醫美修護及高毛利美容生醫產品概念部分重疊。
Sources（14）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.